Published :
Tables : 44
Figures : 44
Category : Healthcare
No. of Pages : 232
Report Code : HC-U4540
Asia Pacific Pharmaceutical Contract Manufacturing Market is estimated to register a CAGR of over 7.6% during the forecast period 2020 to 2027 FutureWise Market Research has instantiated a report that provides an intricate analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Asia Pacific Pharmaceutical Contract Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Asia Pacific Pharmaceutical Contract Manufacturing Market: • Aenova Group • Baxter BioPharma Solutions • Boehringer Ingelheim • Catalent Inc. • Famar S.A. • Hospira, Inc. • Jubilant Life Sciences Ltd. • Lonza Group • Patheon Inc. • Pfizer CentreSource • Recipharm AB • Vetter Pharma International GmbH (Note: The list of the major players will be updated with the latest market scenario and trends) Asia Pacific Pharmaceutical Contract Manufacturing Market Segmentation: By Category • Pharmaceutical Industry • Biopharmaceutical Industry By Product • Active Pharmaceutical Ingredients (API) o Branded API Manufacturing o Generic API Manufacturing • Finished Dosage Formulations (FDF) o Solid Dosage o Oral Liquids o Parenteral/Injectables o Other FDFs By Phase • Clinical Manufacturing • Commercial Manufacturing By Type • Sterile Products • Non-Sterile Products By Therapeutic Application • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications By Region • Japan • China • India • Australia and New Zealand • ASEAN • Rest of Asia Pacific Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Asia Pacific Pharmaceutical Contract Manufacturing Market By Category, By Product, By Phase, By Type, By Therapeutic Application and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— Asia Pacific. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Asia Pacific Pharmaceutical Contract Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Asia Pacific Pharmaceutical Contract Manufacturing Market: • Aenova Group • Baxter BioPharma Solutions • Boehringer Ingelheim • Catalent Inc. • Famar S.A. • Hospira, Inc. • Jubilant Life Sciences Ltd. • Lonza Group • Patheon Inc. • Pfizer CentreSource • Recipharm AB • Vetter Pharma International GmbH (Note: The list of the major players will be updated with the latest market scenario and trends) Asia Pacific Pharmaceutical Contract Manufacturing Market Segmentation: By Category • Pharmaceutical Industry • Biopharmaceutical Industry By Product • Active Pharmaceutical Ingredients (API) o Branded API Manufacturing o Generic API Manufacturing • Finished Dosage Formulations (FDF) o Solid Dosage o Oral Liquids o Parenteral/Injectables o Other FDFs By Phase • Clinical Manufacturing • Commercial Manufacturing By Type • Sterile Products • Non-Sterile Products By Therapeutic Application • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications By Region • Japan • China • India • Australia and New Zealand • ASEAN • Rest of Asia Pacific Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Asia Pacific Pharmaceutical Contract Manufacturing Market By Category, By Product, By Phase, By Type, By Therapeutic Application and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— Asia Pacific. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Asia Pacific Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Asia Pacific Pharmaceutical Contract Manufacturing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Category Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Pharmaceutical Industry 7.2. Biopharmaceutical Industry 8. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Active Pharmaceutical Ingredients (API) 8.1.1. Branded API Manufacturing 8.1.2. Generic API Manufacturing 8.2. Finished Dosage Formulations (FDF) 8.2.1. Solid Dosage 8.2.2. Oral Liquids 8.2.3. Parenteral/Injectables 8.2.4. Other FDFs 9. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Phase Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Clinical Manufacturing 9.2. Commercial Manufacturing 10. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Sterile Products 10.2. Non-Sterile Products 11. Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Therapeutic Application Historical Analysis and Forecast 2020-2027 (USD Million) 11.1. Infectious Diseases 11.2. Oncology 11.3. Metabolic Disorders 11.4. Cardiovascular Disorders 11.5. Central Nervous System 11.6. Pulmonary Disorders 11.7. Gastrointestinal Disorders 11.8. Other Therapeutic Applications 12. Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 13. Market Share Analysis and Competitive Landscape 13.1. Asia Pacific Landscape - Key Players, Revenue and Presence 13.2. Asia Pacific Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 13.3. Asia Pacific Emerging Companies 13.4. Asia Pacific - Market Share Analysis and Key Regional Players 13.5. Asia Pacific Key Player - Growth Matrix 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 14.1. Aenova Group 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Baxter BioPharma Solutions 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Boehringer Ingelheim 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. Catalent Inc. 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5. Famar S.A. 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6. Hospira, Inc. 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Jubilant Life Sciences Ltd. 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Lonza Group 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Patheon Inc. 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10.Pfizer CentreSource 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 14.11.Recipharm AB 14.11.1. Company Overview 14.11.2. Product Portfolio 14.11.3. SWOT Analysis 14.11.4. Financial Overview 14.11.5. Strategic Overview 14.12.Vetter Pharma International GmbH 14.12.1. Company Overview 14.12.2. Product Portfolio 14.12.3. SWOT Analysis 14.12.4. Financial Overview 14.12.5. Strategic Overview 15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics